Introduction Glioblastoma is the most common and malignant primary brain tumour with
median survival of 14.6 months. Personalised medicine aims to improve survival by …

Although novel knowledge has been acquired on the molecular landscape of glioblastoma
(GBM), a relatively few steps forward have been made regarding its therapy. With the …

Recent multi-omics studies, including proteomics, transcriptomics, genomics, and
metabolomics have revealed the critical role of post-translational modifications (PTMs) in the …

Glioblastoma (GBM) represents an aggressive brain tumor, characterized by intra-and inter-
tumoral heterogeneity and therapy resistance, leading to unfavourable prognosis. An …

Glioma is the most common primary intracranial tumor in adults, with high incidence,
recurrence, and mortality rates. Tumor-associated neutrophils (TANs) are essential …

Worldwide, the number of individuals suffering from visual impairment, as well as those
affected by blindness, is about 600 million and it will further increase in the coming decades …

Background Glioblastoma (GBM) is an extremely aggressive form of brain tumor with low
survival rates. Current treatments such as chemotherapy, radiation, and surgery are …

In the era of digitalization, the biomedical sector has been affected by the spread of artificial
intelligence. In recent years, the possibility of using deep and machine learning methods for …

Tumor microenvironment (TME), composed by a milieu of stromal and immune cells, is one
of the critical players in glioblastoma (GBM) progression and heterogeneity. GBM …

L'insorgenza e la progressione del glioblastoma (GBM) è supportata da un ampio range di
fattori che influenzano lo stato metabolico, il setting genetico ed epigenetico del tumore e …